Astonea Labs Ltd
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies[1]
- Market Cap ₹ 282 Cr.
- Current Price ₹ 268
- High / Low ₹ 301 / 118
- Stock P/E 62.3
- Book Value ₹ 54.4
- Dividend Yield 0.00 %
- ROCE 10.3 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 4.93 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Working capital days have increased from 43.9 days to 74.2 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 30 | 67 | 80 | 97 | 148 | |
| 24 | 60 | 68 | 82 | 134 | |
| Operating Profit | 6 | 7 | 12 | 15 | 13 |
| OPM % | 19% | 11% | 15% | 16% | 9% |
| 0 | 0 | 0 | 0 | 1 | |
| Interest | 2 | 2 | 3 | 4 | 3 |
| Depreciation | 4 | 4 | 4 | 5 | 5 |
| Profit before tax | 1 | 1 | 5 | 7 | 6 |
| Tax % | 57% | 39% | 24% | 24% | 20% |
| 0 | 1 | 4 | 5 | 5 | |
| EPS in Rs | 0.62 | 1.68 | 5.36 | 6.93 | 4.30 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 30% |
| TTM: | 52% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 97% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 98% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 22% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 8 | 8 | 11 |
| Reserves | 3 | 4 | 4 | 11 | 47 |
| 30 | 36 | 42 | 53 | 43 | |
| 16 | 20 | 26 | 32 | 46 | |
| Total Liabilities | 53 | 64 | 81 | 103 | 146 |
| 21 | 21 | 22 | 25 | 31 | |
| CWIP | 0 | 0 | 2 | 5 | 8 |
| Investments | 0 | 0 | 0 | 0 | 6 |
| 32 | 44 | 57 | 73 | 101 | |
| Total Assets | 53 | 64 | 81 | 103 | 146 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -5 | -1 | 8 | 9 | -14 | |
| -3 | -3 | -8 | -11 | -20 | |
| 8 | 4 | -0 | 2 | 34 | |
| Net Cash Flow | -0 | 0 | -1 | -0 | 0 |
| Free Cash Flow | -8 | -4 | 0 | -2 | -34 |
| CFO/OP | -75% | -9% | 71% | 70% | -89% |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 235 | 104 | 116 | 142 | 129 |
| Inventory Days | 136 | 121 | 161 | 161 | 125 |
| Days Payable | 273 | 128 | 149 | 144 | 150 |
| Cash Conversion Cycle | 98 | 97 | 128 | 159 | 103 |
| Working Capital Days | 98 | 33 | 28 | 29 | 74 |
| ROCE % | 8% | 17% | 17% | 10% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Actual Monthly Production - Capsules (Hard) Millions |
|
|||
| Actual Monthly Production - Ointments Millions |
||||
| Actual Monthly Production - Tablets Millions |
||||
| Actual Monthly Production - Toothpaste Millions |
||||
| Capacity Utilization - Capsules (Hard) % |
||||
| Capacity Utilization - Ointments % |
||||
| Capacity Utilization - Tablets % |
||||
| Capacity Utilization - Toothpaste % |
||||
| Installed Monthly Capacity - Capsules (Hard) Millions |
||||
| Installed Monthly Capacity - Ointments Millions |
||||
| Installed Monthly Capacity - Tablets Millions |
||||
| Installed Monthly Capacity - Toothpaste Millions |
||||
| Revenue Concentration - Top 10 Clients % |
||||
| Employee Count Number |
||||
Extracted by Screener AI
Documents
Announcements
-
Submission Of Half-Yearly Disclosure On Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (LODR) Regulations 2015 As Amended
30 May - Submitted related party transaction disclosure for half year ended 31 March 2026.
-
Re-Appointment Of Secretarial Auditor
30 May - Board re-appointed Sahil Malhotra as Secretarial Auditor for FY 2026-27 on 30 May 2026.
-
Re-Appointment Of Cost Auditor
30 May - Mr. Mukesh Kumar Gupta re-appointed as Cost Auditor for FY 2026-27 on 30 May 2026.
-
Re-Appointment Of Tax Auditor
30 May - Astonea Labs reappointed M/s. Avnish Sharma & Associates as tax auditor for FY 2026-27.
-
Statement Of Deviation & Variation For The Half Year Ended 31.03.2026
30 May - Astonea Labs disclosed IPO fund deviation, reallocating Rs 6.25 crore to Damaira Pharmaceuticals stake, approved by board and shareholders.
Business Verticals[1]
a) Own brands: ** Its own brand include "Glow Up" (cosmetics) and "Regero" (pharmaceuticals).
b) Contract Manufacturing**: It also engages in contract manufacturing for domestic and international clients, serving markets like the USA, Bolivia, Guatemala, Botswana, Iraq, and Yemen.